Pulsed Dye Laser, Rosacea
Conditions
Brief summary
This study was designed as a single-center, prospective, randomized controlled trial and included 80 patients with rosacea treated at the Department of Dermatology, Jiangsu Provincial People's Hospital. All patients received pulsed dye laser therapy (pulsed dye laser system; Cynosure (Beijing) Medical Technology Co., Ltd., China). Treatment energy was adjusted according to individual clinical responses, with no concomitant therapies administered. All patients were informed of study-related precautions and provided written informed consent prior to enrollment. Each patient underwent a single session of bilateral facial 595-nm pulsed dye laser treatment with randomized pulse durations of 6 ms or 10 ms, using a fluence of 9-11 J/cm² and a 7-mm spot size, followed by post-treatment epidermal cooling. Skin imaging was performed at baseline and at 1 month after treatment. At 3 and 7 days post-treatment, erythema improvement, pain visual analog scale (VAS) scores, and adverse events were assessed using questionnaires. At 1 month, treatment efficacy and safety were evaluated based on erythema improvement, patient satisfaction, Clinical Erythema Assessment (CEA) score, Investigator's Global Assessment (IGA) score, Rosacea Area and Severity Index (RASI) score, skin imaging analysis, and adverse event records.
Interventions
DEVICEpulse duration, 6ms
The PDL (595 nm, VBeam, Candela/Syneron, Wayland, MA) settings were: Energy range, 9-11 J/cm2\[Y7.1\]; spot size, 7 mm; pulse duration, 6ms; with a dynamic spray cooling device was used during this study.
DEVICEpulse duration, 10ms
The PDL (595 nm, VBeam, Candela/Syneron, Wayland, MA) settings were: Energy range, 9-11 J/cm2\[Y7.1\]; spot size, 7 mm; pulse duration, 10ms; with a dynamic spray cooling device was used during this study.
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* participants aged 20-60 years with a clinical diagnosis of erythematotelangiectatic rosacea, in otherwise good general health, who provided written informed consent and agreed to complete the study procedures.
Exclusion criteria
1. active infection at the treatment site; 2. a history of keloid formation or a tendency to develop keloids; 3. a history of photosensitivity disorders; 4. facial laser treatment, chemical peeling, or facial surgery within the past 3 months; 5. pregnancy or breastfeeding; 6. concomitant treatment for rosacea; 7. participation in another clinical trial within 30 days prior to screening; 8. any other condition deemed by the investigator to make the subject unsuitable for participation; 9. presence of other facial inflammatory skin diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Erythema Assessment (CEA) score | From enrollment to the end of treatment at 4 weeks | Clinician's Erythema Assessment (CEA) scale Scores 0= clear Clear skin with no signs of erythema 1 = Almost clear Slight redness; almost clear 2=mild Definite redness; mild erythema 3 = moderate Marked redness; moderate erythema 4= severe Fiery redness; severe erythema This scale assesses the average facial erythema condition over 24 hours.For CEA scoring, which were evaluated masked by two well-trained dermatologists. when two dermatologists have different scores, the one with the higher score will be included in the statistics |
Countries
China
Outcome results
None listed